[2] Siwei N , Zhuozhi W , Maria M C , et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics[J]. Antibody Therapeutics(1):1. [3]Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation; [4]骆群...
This invention refers to a linear single chain recombinant trispecific\nantibody (scTsAb). This\ntrispecific antibody is composed of an anti-carcinoembryonic antigen (CEA), an\nanti-CD3, and an\nanti-CD28 (CEA-scTsAb). More specifically, a Fc linking peptide fuses the anti-\nCEA single chain...
[1]Edward Seung et al. A trispecificantibody targeting HER2 and T cells inhibits breast cancer growth via CD4cells. Nature(2022). [2]Nature:癌症免疫疗法新突破——三特异性抗体(来源:医药魔方Pro)
[2] Siwei N , Zhuozhi W , Maria M C , et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics[J]. Antibody Therapeutics(1):1. [3]Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation; [4]骆群...
参考3 参考:1.惠和生物官方发布;2.Edward Seung et al. A trispecificantibodytargeting HER2 and T cells inhibits breast cancer growth via CD4cells. Nature(2022);3.https://doi.org/10.1080/19420862.2016.1162932
(e.g., 4-1BB, OX40, GITR, CD27) or immunoglobulin superfamily (e.g., CD28, ICOS), can be used to boost immune responses to CD3+ T-cell-engaging therapies. Notably, an agonistic anti-4-1BB antibody was shown to restore the functionality of exhausted CD8+ tumour-infiltrating ...
Anti-CD3 anti-CD20 bispecific antibody、Anti-CD3 anti-CD20 bispecific antibody(Genmab A/S)、epcoritamab-bysp + [7] 靶点 CD20 x CD3 作用方式 抑制剂、刺激剂 作用机制 CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、CD3刺激剂(T细胞表面糖蛋白CD3复合体刺激剂) ...
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies PIT565,一种用于治疗B细胞恶性肿瘤的一流抗CD19、抗CD3、抗CD2三特异性抗体 相关领域 抗体 CD19 免疫学 医学 B细胞 CD3型 免疫系统 CD8型 ...
3. The antibody according to claim 1, wherein the antibody is a full-length antibody. 4. The antibody according to claim 1, wherein the antibody is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4. 5. The antibody according to claim 1, wherein the ...
Schoonjans, et al., Fab Chains as an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives, The Journal of Immunology, 2000, vol. 165, pp. 7050-7057. Schroder et al., The Peptides, Vol. pp. 76-136, 1965, Academic Press. ...